Danaher Corporation
DHRHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeDanaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. With a market capitalization of $144.27B, it sits in large-cap territory. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Market Cap
$144.27B
Beta
0.81
P/E (TTM)
36.58
P/E (Fwd)
22.08
EPS (TTM)
$5.61
EPS (Fwd)
$9.30
ROE
7.6%
ROA
4.0%
Cash
$4.35B
Total Debt
$27.86B
Free CF
$4.33B
52W Change
7.8%
Annual Financials
Cash vs Debt
Where DHR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DHR finished 8.48% above its 150-day moving average ($193.50) and 3.73% above its 200-day moving average ($202.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DHR overbought or oversold?
At the September 3, 2026 close, DHR's RSI(14) was 57.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Danaher Corporation carries $27.86B in total debt against $4.35B in cash reserves — debt is roughly 6.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $4.33B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 7.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $26.64B (2022) to $24.57B (2025).
Danaher Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing DHR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.